AI in drug discovery

News

MSD's $349m alliance with Variational, and other AI news

MSD signs $345m alliance with Variational AI, plus updates on AI in drug discovery projects from Bio Protocol, Dalton Tx, Virginia Tech, and Insilico.

News

Lilly offers AI discovery models to biotech partners

Eli Lilly is offering AI-powered drug discovery models developed at a cost of around $1 billion to biotech companies for free.

R&D

The impact of generative AI on protein design for drug disco...

Artificial Intelligence (AI) is at the heart of the latest global transformation, not least within the biopharmaceutical industry.

R&D

pharmaphorum podcast Episode 191a, Ben Sidders

Ben Sidders on integrating causality in AI for R&D success

Ben Sidders, chief scientific officer at Biorelate, discusses leveraging advanced data science methods to transform the focus and impact of R&D.

R&D

Post-hype, pre-value: The real AI-pharma shift starts now

The first era of AI in pharma was built on potential. This next era will be built on proof, reinforcing even greater potential.

News

Caris swells its planned IPO, seeking $5.7bn valuation

AI-powered techbio firm Caris Life Sciences has raised the target price for its IPO, pointing to strong demand among investors.

MSD's $349m alliance with Variational, and other AI news

Lilly offers AI discovery models to biotech partners

The impact of generative AI on protein design for drug disco...

Ben Sidders on integrating causality in AI for R&D success

Post-hype, pre-value: The real AI-pharma shift starts now

Caris swells its planned IPO, seeking $5.7bn valuation

NHS to offer Wegovy to a million more people in England

Using AI-driven synthetic personas to take your insights fur...

AI in drug discovery

Editor's Picks